Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
At least 15 dual-payload ADCs will be discussed.
Ikena, Senti and others look to clinical presentations at AACR.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
